|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S1
|
$50,000
|
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
Innovation Corp Program and Commercialization Planning for Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
3R43CA225169-01S1
|
$49,999
|
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
Fluorescent Nanodiamonds for Multiplexed Imaging and Diagnostics
|
1R43CA232901-01
|
$291,083
|
|
SHENDEROVA, OLGA
|
ADAMAS NANOTECHNOLOGIES, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation
|
1R43CA232977-01
|
$298,444
|
|
MARLEAU, ANNETTE
|
AETHLON MEDICAL, INC.
|
|
Training African Pathologists in Cancer Diagnosis
|
1R13CA232439-01
|
$38,120
|
|
WILSON, MICHAEL
|
AFRICAN STRATEGIES /ADVANCING PATHOLOGY
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Synergistic co-targeting of pro-apoptotic BAX and anti-apoptotic BCL-XL in cancer
|
1F31CA236434-01
|
$44,524
|
|
LOPEZ-ARROYO, ANDREA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Highly Multiplexed Nanoscale Mass Spectrometric Imaging of Cancer Tissues
|
1R43CA236097-01
|
$300,000
|
|
LIM, MARK
|
AMBERGEN, INC
|
|
11th AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
|
1R13CA236113-01
|
$74,000
|
|
FOTI, MARGARET
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
Integrative Molecular Epidemiology Workshop
|
2R25CA174664-06
|
$258,400
|
|
SELLERS, THOMAS
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
Couple Communication in Cancer: A Multi-Method Examination
|
3R01CA201179-03S1
|
$227,376
|
|
LANGER, SHELBY
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Therapeutic peptide for hepatocellular carcinoma
|
1R43CA232947-01
|
$299,983
|
|
PANDEY, NIRANJAN
|
ASCLEPIX THERAPEUTICS, LLC
|
|
Create three-member project team to refine commercialization plans for AML-Mutation Counter, a tool to detect residual and recurrent leukemia.
|
3R41CA213690-01S1
|
|
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
|
P53-dependent immunogenic DCs in the tumor microenvironment
|
1R50CA232983-01
|
$203,853
|
|
SHARMA, MADHAV
|
AUGUSTA UNIVERSITY
|
|
DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer
|
1R44CA232963-01
|
$299,937
|
|
GLODE, MIKE
|
AURORA ONCOLOGY, INC.
|
|
Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy
|
1R44CA233143-01
|
$218,588
|
|
LAMPI HERMANSON, DAVID
|
B-MOGEN BIOTECHNOLOGIES, INC.
|
|
Integrative Oncology: From Research to Practical Applications
|
1R13CA236121-01
|
$5,000
|
|
RAO, SANTOSH
|
BANNER HEALTH
|
|
Identifying and Targeting Onocgenic MYC Enhancer Control in Pediatric Tumors
|
3R01CA215452-02S2
|
$45,800
|
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
2/2: UHCOP-DLDCCC alliance: Cancer drug discovery/development and education
|
1P20CA221729-01A1
|
$258,006
|
|
MATZUK, MARTIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Minority PDX Development and Trial Center: Baylor College of Medicine and MD Anderson Cancer Center Collaboration on Mechanistic Studies to Dissect and Combat Health Disparities in Cancer
|
1U54CA233223-01
|
$6,353,982
|
|
MITSIADES, NICHOLAS
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
|
1U01DE028233-01
|
$536,395
|
|
SIKORA, ANDREW
|
BAYLOR COLLEGE OF MEDICINE
|
|
Combating Subclonal Evolution of Resistant Cancer Phenotypes
|
5U54CA209978-03
|
$2,154,776
|
|
BILD, ANDREA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Genetics Professional Education in a Global Community of Practice
|
2R25CA171998-06
|
$280,269
|
|
BLAZER, KATHLEEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Human natural killer cells: Advancing biology and clinical applications
|
7R35CA210087-02
|
$992,214
|
$992,214
|
CALIGIURI, MICHAEL
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine
|
5R01CA077544-16
|
$539,228
|
$539,228
|
DIAMOND, DON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection
|
5R01CA181045-04
|
$710,976
|
$710,976
|
DIAMOND, DON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
City of Hope Lymphoma SPORE
|
3P50CA107399-10S1
|
$300,000
|
$75,000
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Image-guided irradiation safely intensifies HSCT regimen for refractory leukemia
|
5R01CA195519-02
|
$272,213
|
$272,213
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Yes 2 Success
|
1R25CA233431-01
|
$485,999
|
|
KITTLES, RICK
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Optimizing Busulfan: Efficacy Toxicity and Pharmacometabolomics
|
5R01CA182963-05
|
$515,038
|
$515,038
|
MCCUNE, JEANNINE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S1
|
$73,297
|
$7,330
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S2
|
$124,999
|
$12,500
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
5P30CA033572-34
|
$2,446,682
|
$244,668
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Mentored Clinical Scientist Research Career Development Award (Parent K08)
|
1K08CA234394-01
|
$249,042
|
|
SLAVIN, THOMAS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Refinement of CAR-T-Cell therapy targeting glioblastomas
|
1F99CA234923-01
|
$30,024
|
|
WANG, DONGRUI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Stem Cell Gene Therapy Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patient
|
5U01CA183012-04
|
$312,304
|
$312,304
|
ZAIA, JOHN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Effects of PGE2 on reconstitution of hematopoiesis and immunity after UCBT
|
5R01CA183605-05
|
$894,037
|
$894,037
|
BOUSSIOTIS, VASSILIKI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Role of Vitamin B5 and Coenzyme A Metabolism in PI3K Driven Tumorigenesis
|
4R00CA194314-03
|
$249,000
|
|
DIBBLE, CHRISTIAN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Tissue-specific genetic interactions in cancer
|
1R01CA232372-01
|
$505,643
|
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Parallel and high throughput isolation of cfDNA to target detection of rare, highly conserved nucleotide polymorphisms
|
1R43CA228923-01A1
|
$286,548
|
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Parallel and high throughput isolation of cancer cell derived extracellular vesicles
|
1R43CA232848-01
|
$239,138
|
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia
|
1R44CA224848-01A1
|
$348,768
|
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Cancer Imaging and Therapy Analysis Platform (CITAP)
|
2R44CA213601-02
|
$817,362
|
|
GARGESHA, MADHUSUDHANA
|
BIOINVISION, INC.
|
|
Biomedical Engineering Society Annual Meeting
|
1R13EB026960-01
|
$5,000
|
|
SETTON, LORI
|
BIOMEDICAL ENGINEERING SOCIETY
|
Total relevant funding to Organ Transplantation Research for this search: $57,569,357
|